Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study

David B Price, Anna Rigazio, Jonathan D Campbell, Eugene R Bleecker, Christopher J Corrigan, Mike Thomas, Sally E Wenzel, Andrew M Wilson, Mary Buatti Small, Gokul Gopalan, Valerie L Ashton, Anne Burden, Elizabeth V Hillyer, Marjan Kerkhof, Ian D Pavord

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

BACKGROUND: Elevated sputum eosinophil counts predict asthma exacerbations and responsiveness to inhaled corticosteroids but are impractical to measure in primary care. We investigated the relation between blood eosinophil count and prospective annual asthma outcomes for a large UK cohort.

METHODS: This historical cohort study used anonymised medical record data to identify primary care patients with asthma aged 12-80 years with 2 years of continuous records, including 1 year before (baseline) and 1 year after (outcome) their most recent eosinophil count. Negative binomial regression was used to compare outcome exacerbation rates and logistic regression to compare odds of asthma control for patients with blood eosinophil counts of 400 cells per μL or less versus greater than 400 cells per μL, adjusting for age, sex, body-mass index, smoking status, and Charlson comorbidity index. The study is registered at ClinicalTrials.gov, number NCT02140541.

FINDINGS: Overall, 20 929 (16%) of 130 248 patients had blood eosinophil counts greater than 400 cells per μL. During the outcome year, these patients experienced significantly more severe exacerbations (adjusted rate ratio [RR] 1·42, 95% CI 1·36-1·47) and acute respiratory events (RR 1·28, 1·24-1·33) than those with counts of 400 cells per μL or less. They also had significantly lower odds of achieving overall asthma control (OR 0·74, 95% CI 0·72-0·77), defined as limited reliever use and no asthma-related hospital attendance or admission, acute course of oral corticosteroids, or prescription for antibiotics. Exacerbation rates increased progressively with nine ascending categories of blood eosinophil count as compared with a reference category of 200 cells per μL or less.

INTERPRETATION: Patients with asthma and blood eosinophil counts greater than 400 cells per μL experience more severe exacerbations and have poorer asthma control. Furthermore, a count-response relation exists between blood eosinophil counts and asthma-related outcomes. Blood eosinophil counts could add predictive value to Global Initiative for Asthma control-based risk assessment.

FUNDING: Teva Pharmaceuticals.

Original languageEnglish
Pages (from-to)849-858
Number of pages10
JournalThe Lancet. Respiratory medicine
Volume3
Issue number11
Early online date19 Oct 2015
DOIs
Publication statusPublished - Nov 2015

Fingerprint

Eosinophils
Cohort Studies
Asthma
Primary Health Care
Adrenal Cortex Hormones
Cell Count
Respiratory Rate
Sputum
Medical Records
Prescriptions
Comorbidity
Body Mass Index
Logistic Models
Smoking
Anti-Bacterial Agents

Keywords

  • Asthma
  • Blood Eosinophil Count

Cite this

Price, D. B., Rigazio, A., Campbell, J. D., Bleecker, E. R., Corrigan, C. J., Thomas, M., ... Pavord, I. D. (2015). Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. The Lancet. Respiratory medicine, 3(11), 849-858. https://doi.org/10.1016/S2213-2600(15)00367-7

Blood eosinophil count and prospective annual asthma disease burden : a UK cohort study. / Price, David B; Rigazio, Anna; Campbell, Jonathan D; Bleecker, Eugene R; Corrigan, Christopher J; Thomas, Mike; Wenzel, Sally E; Wilson, Andrew M; Small, Mary Buatti; Gopalan, Gokul; Ashton, Valerie L; Burden, Anne; Hillyer, Elizabeth V; Kerkhof, Marjan; Pavord, Ian D.

In: The Lancet. Respiratory medicine, Vol. 3, No. 11, 11.2015, p. 849-858.

Research output: Contribution to journalArticle

Price, DB, Rigazio, A, Campbell, JD, Bleecker, ER, Corrigan, CJ, Thomas, M, Wenzel, SE, Wilson, AM, Small, MB, Gopalan, G, Ashton, VL, Burden, A, Hillyer, EV, Kerkhof, M & Pavord, ID 2015, 'Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study', The Lancet. Respiratory medicine, vol. 3, no. 11, pp. 849-858. https://doi.org/10.1016/S2213-2600(15)00367-7
Price, David B ; Rigazio, Anna ; Campbell, Jonathan D ; Bleecker, Eugene R ; Corrigan, Christopher J ; Thomas, Mike ; Wenzel, Sally E ; Wilson, Andrew M ; Small, Mary Buatti ; Gopalan, Gokul ; Ashton, Valerie L ; Burden, Anne ; Hillyer, Elizabeth V ; Kerkhof, Marjan ; Pavord, Ian D. / Blood eosinophil count and prospective annual asthma disease burden : a UK cohort study. In: The Lancet. Respiratory medicine. 2015 ; Vol. 3, No. 11. pp. 849-858.
@article{933108501627406b8a67359d02761e28,
title = "Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study",
abstract = "BACKGROUND: Elevated sputum eosinophil counts predict asthma exacerbations and responsiveness to inhaled corticosteroids but are impractical to measure in primary care. We investigated the relation between blood eosinophil count and prospective annual asthma outcomes for a large UK cohort.METHODS: This historical cohort study used anonymised medical record data to identify primary care patients with asthma aged 12-80 years with 2 years of continuous records, including 1 year before (baseline) and 1 year after (outcome) their most recent eosinophil count. Negative binomial regression was used to compare outcome exacerbation rates and logistic regression to compare odds of asthma control for patients with blood eosinophil counts of 400 cells per μL or less versus greater than 400 cells per μL, adjusting for age, sex, body-mass index, smoking status, and Charlson comorbidity index. The study is registered at ClinicalTrials.gov, number NCT02140541.FINDINGS: Overall, 20 929 (16{\%}) of 130 248 patients had blood eosinophil counts greater than 400 cells per μL. During the outcome year, these patients experienced significantly more severe exacerbations (adjusted rate ratio [RR] 1·42, 95{\%} CI 1·36-1·47) and acute respiratory events (RR 1·28, 1·24-1·33) than those with counts of 400 cells per μL or less. They also had significantly lower odds of achieving overall asthma control (OR 0·74, 95{\%} CI 0·72-0·77), defined as limited reliever use and no asthma-related hospital attendance or admission, acute course of oral corticosteroids, or prescription for antibiotics. Exacerbation rates increased progressively with nine ascending categories of blood eosinophil count as compared with a reference category of 200 cells per μL or less.INTERPRETATION: Patients with asthma and blood eosinophil counts greater than 400 cells per μL experience more severe exacerbations and have poorer asthma control. Furthermore, a count-response relation exists between blood eosinophil counts and asthma-related outcomes. Blood eosinophil counts could add predictive value to Global Initiative for Asthma control-based risk assessment.FUNDING: Teva Pharmaceuticals.",
keywords = "Asthma, Blood Eosinophil Count",
author = "Price, {David B} and Anna Rigazio and Campbell, {Jonathan D} and Bleecker, {Eugene R} and Corrigan, {Christopher J} and Mike Thomas and Wenzel, {Sally E} and Wilson, {Andrew M} and Small, {Mary Buatti} and Gokul Gopalan and Ashton, {Valerie L} and Anne Burden and Hillyer, {Elizabeth V} and Marjan Kerkhof and Pavord, {Ian D}",
note = "Copyright {\circledC} 2015 Elsevier Ltd. All rights reserved. Funding: Teva Pharmaceuticals.",
year = "2015",
month = "11",
doi = "10.1016/S2213-2600(15)00367-7",
language = "English",
volume = "3",
pages = "849--858",
journal = "The Lancet. Respiratory medicine",
issn = "2213-2600",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Blood eosinophil count and prospective annual asthma disease burden

T2 - a UK cohort study

AU - Price, David B

AU - Rigazio, Anna

AU - Campbell, Jonathan D

AU - Bleecker, Eugene R

AU - Corrigan, Christopher J

AU - Thomas, Mike

AU - Wenzel, Sally E

AU - Wilson, Andrew M

AU - Small, Mary Buatti

AU - Gopalan, Gokul

AU - Ashton, Valerie L

AU - Burden, Anne

AU - Hillyer, Elizabeth V

AU - Kerkhof, Marjan

AU - Pavord, Ian D

N1 - Copyright © 2015 Elsevier Ltd. All rights reserved. Funding: Teva Pharmaceuticals.

PY - 2015/11

Y1 - 2015/11

N2 - BACKGROUND: Elevated sputum eosinophil counts predict asthma exacerbations and responsiveness to inhaled corticosteroids but are impractical to measure in primary care. We investigated the relation between blood eosinophil count and prospective annual asthma outcomes for a large UK cohort.METHODS: This historical cohort study used anonymised medical record data to identify primary care patients with asthma aged 12-80 years with 2 years of continuous records, including 1 year before (baseline) and 1 year after (outcome) their most recent eosinophil count. Negative binomial regression was used to compare outcome exacerbation rates and logistic regression to compare odds of asthma control for patients with blood eosinophil counts of 400 cells per μL or less versus greater than 400 cells per μL, adjusting for age, sex, body-mass index, smoking status, and Charlson comorbidity index. The study is registered at ClinicalTrials.gov, number NCT02140541.FINDINGS: Overall, 20 929 (16%) of 130 248 patients had blood eosinophil counts greater than 400 cells per μL. During the outcome year, these patients experienced significantly more severe exacerbations (adjusted rate ratio [RR] 1·42, 95% CI 1·36-1·47) and acute respiratory events (RR 1·28, 1·24-1·33) than those with counts of 400 cells per μL or less. They also had significantly lower odds of achieving overall asthma control (OR 0·74, 95% CI 0·72-0·77), defined as limited reliever use and no asthma-related hospital attendance or admission, acute course of oral corticosteroids, or prescription for antibiotics. Exacerbation rates increased progressively with nine ascending categories of blood eosinophil count as compared with a reference category of 200 cells per μL or less.INTERPRETATION: Patients with asthma and blood eosinophil counts greater than 400 cells per μL experience more severe exacerbations and have poorer asthma control. Furthermore, a count-response relation exists between blood eosinophil counts and asthma-related outcomes. Blood eosinophil counts could add predictive value to Global Initiative for Asthma control-based risk assessment.FUNDING: Teva Pharmaceuticals.

AB - BACKGROUND: Elevated sputum eosinophil counts predict asthma exacerbations and responsiveness to inhaled corticosteroids but are impractical to measure in primary care. We investigated the relation between blood eosinophil count and prospective annual asthma outcomes for a large UK cohort.METHODS: This historical cohort study used anonymised medical record data to identify primary care patients with asthma aged 12-80 years with 2 years of continuous records, including 1 year before (baseline) and 1 year after (outcome) their most recent eosinophil count. Negative binomial regression was used to compare outcome exacerbation rates and logistic regression to compare odds of asthma control for patients with blood eosinophil counts of 400 cells per μL or less versus greater than 400 cells per μL, adjusting for age, sex, body-mass index, smoking status, and Charlson comorbidity index. The study is registered at ClinicalTrials.gov, number NCT02140541.FINDINGS: Overall, 20 929 (16%) of 130 248 patients had blood eosinophil counts greater than 400 cells per μL. During the outcome year, these patients experienced significantly more severe exacerbations (adjusted rate ratio [RR] 1·42, 95% CI 1·36-1·47) and acute respiratory events (RR 1·28, 1·24-1·33) than those with counts of 400 cells per μL or less. They also had significantly lower odds of achieving overall asthma control (OR 0·74, 95% CI 0·72-0·77), defined as limited reliever use and no asthma-related hospital attendance or admission, acute course of oral corticosteroids, or prescription for antibiotics. Exacerbation rates increased progressively with nine ascending categories of blood eosinophil count as compared with a reference category of 200 cells per μL or less.INTERPRETATION: Patients with asthma and blood eosinophil counts greater than 400 cells per μL experience more severe exacerbations and have poorer asthma control. Furthermore, a count-response relation exists between blood eosinophil counts and asthma-related outcomes. Blood eosinophil counts could add predictive value to Global Initiative for Asthma control-based risk assessment.FUNDING: Teva Pharmaceuticals.

KW - Asthma

KW - Blood Eosinophil Count

U2 - 10.1016/S2213-2600(15)00367-7

DO - 10.1016/S2213-2600(15)00367-7

M3 - Article

C2 - 26493938

VL - 3

SP - 849

EP - 858

JO - The Lancet. Respiratory medicine

JF - The Lancet. Respiratory medicine

SN - 2213-2600

IS - 11

ER -